AstraZeneca Investor Day Presentation Deck slide image

AstraZeneca Investor Day Presentation Deck

Conclusions 25 ● • A single priming dose of tremelimumab plus regular interval durvalumab with the STRIDE (T300+D) regimen statistically significantly improved overall survival versus sorafenib Median overall survival was 16.4 months for STRIDE (T300+D) and 13.8 months for sorafenib STRIDE (T300+D) appeared to provide a long-term survival benefit, with a landmark 36-month overall survival of 30.7% ● The HIMALAYA study was a large, Phase 3 study that included a global, heterogeneous population, representative of patients with uHCC ● ● ● Overall survival for durvalumab monotherapy was noninferior to sorafenib, with a favorable benefit-risk profile Both STRIDE (T300+D) and durvalumab monotherapy had manageable safety profiles, with lower rates of grade 3/4 TRAES and TRAEs leading to discontinuation than sorafenib and no increase in liver toxicity or bleeding risk The STRIDE (T300+D) regimen and durvalumab monotherapy may represent new treatment options for patients with uHCC
View entire presentation